BRPI0509217A8 - oligossacarídeo alginato e seus derivados, sua preparação e seus usos - Google Patents

oligossacarídeo alginato e seus derivados, sua preparação e seus usos

Info

Publication number
BRPI0509217A8
BRPI0509217A8 BRPI0509217A BRPI0509217A BRPI0509217A8 BR PI0509217 A8 BRPI0509217 A8 BR PI0509217A8 BR PI0509217 A BRPI0509217 A BR PI0509217A BR PI0509217 A BRPI0509217 A BR PI0509217A BR PI0509217 A8 BRPI0509217 A8 BR PI0509217A8
Authority
BR
Brazil
Prior art keywords
derivatives
alginate oligosaccharide
oligosaccharide
alginate
preparation
Prior art date
Application number
BRPI0509217A
Other languages
English (en)
Inventor
Huashi Guan
Sun Guangqiang
Geng Meiyu
Xin Xianliang
Zhao Yang
Original Assignee
Ocean Univ China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocean Univ China filed Critical Ocean Univ China
Publication of BRPI0509217A publication Critical patent/BRPI0509217A/pt
Publication of BRPI0509217A8 publication Critical patent/BRPI0509217A8/pt
Publication of BRPI0509217B1 publication Critical patent/BRPI0509217B1/pt
Publication of BRPI0509217B8 publication Critical patent/BRPI0509217B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"oligossacarídeo alginato e seus derivados, sua preparação e seus usos". o presente estudo fornece um oligossacarídeo alginato e seus derivados com grau de polimerização variando de 2 a 22. o oligossacarídeo alginato é composto de ácido manurônico ligado a ácido b-d-manurônico por ligações glicídicas 1,4. os derivados com terminal reduzido na posição 1 do radical carboxila pode ser preparado por degradação oxidativa. o presente estudo também fornece um processo para preparar o oligossacarídeo alginato e seus derivados, que inclui os procedimentos em que uma solução de alginato é reagida por 2 a 6 h num autoclave a ph 2-6 e temperatura de 100-120?, e o ph é ajustado para 7 após a reação ser interrompida, após o que o oligossacarídeo resultante é oxidado na presença de um oxidante para obter um produto da degradação oxidativa. o oligossacarídeo alginato e seus derivados deste método podem ser usados na manufatura de um medicamente para a profilaxia e tratamento de ma e diabetes.
BRPI0509217A 2004-03-24 2005-02-25 derivados de oligossacarídeo alginato, seu uso e seu processo de preparação, e composição farmacêutica BRPI0509217B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410023827.0 2004-03-24
CNA2004100238270A CN1562050A (zh) 2004-03-24 2004-03-24 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用
PCT/CN2005/000226 WO2005089776A1 (en) 2004-03-24 2005-02-25 Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same

Publications (4)

Publication Number Publication Date
BRPI0509217A BRPI0509217A (pt) 2007-09-04
BRPI0509217A8 true BRPI0509217A8 (pt) 2018-03-13
BRPI0509217B1 BRPI0509217B1 (pt) 2020-09-24
BRPI0509217B8 BRPI0509217B8 (pt) 2022-11-16

Family

ID=34480338

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509217A BRPI0509217B8 (pt) 2004-03-24 2005-02-25 derivados de oligossacarídeo alginato, seu uso e seu processo de preparação, e composição farmacêutica

Country Status (19)

Country Link
US (4) US8835403B2 (pt)
EP (1) EP1736160B1 (pt)
JP (1) JP4709203B2 (pt)
KR (1) KR100844918B1 (pt)
CN (1) CN1562050A (pt)
AU (1) AU2005223923B2 (pt)
BR (1) BRPI0509217B8 (pt)
CA (1) CA2561873C (pt)
DK (1) DK1736160T3 (pt)
EA (1) EA011417B1 (pt)
ES (1) ES2552218T3 (pt)
HU (1) HUE028071T2 (pt)
MA (1) MA28971B1 (pt)
NO (1) NO341226B1 (pt)
PL (1) PL1736160T3 (pt)
PT (1) PT1736160E (pt)
UA (1) UA85226C2 (pt)
WO (1) WO2005089776A1 (pt)
ZA (1) ZA200608813B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562050A (zh) 2004-03-24 2005-01-12 中国海洋大学 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用
US20090216705A1 (en) * 2005-04-13 2009-08-27 National Institute Of Advanced Industrial Science And Technology Method for predicting sugar chain structure
WO2009086685A1 (zh) * 2007-12-29 2009-07-16 Dalian Yaweite Bioengineering Co., Ltd. 低分子量海藻酸及其盐、应用、制法及药物组合物、食品
WO2012138698A1 (en) * 2011-04-08 2012-10-11 Ancora Pharmaceuticals Inc. Synthesis of beta-mannuronic acid oligosaccharides
KR101395181B1 (ko) * 2011-08-02 2014-06-10 부경대학교 산학협력단 알긴산 유래 단량체 또는 중합체를 이용한 알긴산 분석법 및 이를 이용한 바이오매스로부터 추출된 알긴산 분석법
CN102936291B (zh) * 2012-11-15 2014-12-31 深圳大学 一种硒化聚甘露糖醛酸制备方法及其应用
GB2529962B (en) * 2013-05-30 2017-11-22 Suzhou Sciscape Bio-Pharmaceutical Tech Co Ltd Composition Comprising Marine-Algae Derived Material and an Inhibitor of an Enzyme which Decomposes the Material
EP3166981A4 (en) 2014-07-09 2018-03-07 Cadena Bio, Inc. Oligosaccharide compositions and methods for producing thereof
FR3024358B1 (fr) * 2014-08-01 2017-11-10 Soc De Courtage Et De Diffusion Codif Int Compositions cosmetiques et complements alimentaires neuro-protecteurs comprenant de l'oligoalginate ayant un degre de polymerisation de 10 pour lutter contre le vieillissement de la peau.
PT3250048T (pt) 2015-01-26 2019-11-18 Cadena Bio Inc Composições de oligossacáridos para utilização como ração para animais e métodos para a sua produção
MX2017009722A (es) * 2015-01-26 2018-02-26 Cadena Bio Inc Composiciones de oligosacaridos para el uso como ingredientes comestibles y metodos para producirlas.
WO2016159554A1 (ko) * 2015-03-27 2016-10-06 전남대학교 산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당 및 이를 유효성분으로 포함하는 조성물
CA2983236A1 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
CN106344593B (zh) * 2015-07-17 2020-01-10 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在制备治疗血管性痴呆药物中的应用
CN106349298B (zh) * 2015-07-17 2021-02-09 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在改善睡眠障碍中的应用
CN106344592A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用
EP3374383A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
WO2017083520A1 (en) * 2015-11-13 2017-05-18 Cadena Bio, Inc. Animal therapeutic and feed compositions and methods of use
CN105395563A (zh) * 2015-12-11 2016-03-16 青岛海洋生物医药研究院股份有限公司 低聚古罗糖醛酸及其衍生物在制备预防和治疗高脂血症及其并发症的药物和保健品中的应用
KR101862459B1 (ko) * 2016-06-21 2018-06-01 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당(ＯｌｉｇｏＭ)을 유효성분으로 포함하는 운동 능력 개선용 조성물
ES2866101T3 (es) * 2016-08-15 2021-10-19 Shanghai Green Valley Pharmaceutical Co Ltd Método para preparar diácido manurónico oligomérico
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
UA127034C2 (uk) 2016-12-30 2023-03-22 Грін Веллі (Шанхай) Фармасьютікалз Ко., Лтд. Композиція мануронової дикарбонової кислоти
JP7330164B2 (ja) 2017-07-18 2023-08-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
KR101893311B1 (ko) * 2017-11-23 2018-08-29 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당(ＯｌｉｇｏＭ)을 포함하는 당뇨의 예방 또는 치료용 조성물
CN110652524A (zh) 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗疼痛中的应用
CN110652517A (zh) 2018-06-29 2020-01-07 上海绿谷制药有限公司 褐藻胶寡糖二酸的组合物
CN110652525A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗炎症中的应用
CN110652523A (zh) 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用
CN110652526A (zh) 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗糖尿病中的应用
CN110652516A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
CN109156615B (zh) * 2018-09-18 2021-12-28 青岛农业大学 一种利用褐藻寡糖提高动物精液品质的方法
CN109221811A (zh) * 2018-09-28 2019-01-18 福州大学 一种水产饲料添加剂褐藻寡糖的制备方法
CN109260210A (zh) * 2018-10-11 2019-01-25 深圳大学 寡聚甘露糖醛酸在抑制总Tau表达、磷酸化和聚集中的应用
CN109674813A (zh) * 2018-12-12 2019-04-26 大连海洋大学 用于提高雄性动物生理功能的复合制剂
CN110151773A (zh) * 2019-05-13 2019-08-23 深圳大学 寡聚古罗糖醛酸在预防和治疗Tau蛋白病药物中的应用
WO2020227876A1 (zh) * 2019-05-13 2020-11-19 深圳大学 寡聚古罗糖醛酸在预防和治疗Tau蛋白病药物中的应用
CN112336742A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 甘露糖醛酸寡糖治疗Th1主导相关疾病的用途
CN112336876A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 用于识别阿尔茨海默病患者中的糖类药物敏感性患者的方法
CN112336861A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过调节氨基酸水平治疗阿尔茨海默病的方法
CN112336860A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过调节肠道微生物治疗阿尔茨海默病的方法
CN110615855B (zh) * 2019-11-01 2020-09-15 农业农村部规划设计研究院 一种生物多糖溶降解制备水溶寡聚衍生物的方法
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
CN110755440B (zh) * 2019-11-20 2023-02-28 中国海洋大学 川芎嗪和甘露糖醛酸的组合物在用于制备治疗血栓性疾病和神经系统疾病的药物中的应用
CN110946804B (zh) * 2020-01-06 2022-07-15 王爱芹 一种预防龋齿和口腔溃疡的漱口水及其制备方法
CN114796243B (zh) * 2021-01-27 2024-04-05 中国海洋大学 一种甘露糖醛酸和益母草碱的药物组合物及其应用
CN115068660A (zh) * 2021-03-11 2022-09-20 吴元通 一种用于创面修复的湿性敷料及其制备方法
CN113730373B (zh) * 2021-07-02 2023-01-24 浙江海洋大学 一种递送姜黄素的zein-AOS复合纳米颗粒及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460945A (en) * 1991-05-30 1995-10-24 Center For Blood Research, Inc. Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response
US5952308A (en) * 1991-07-29 1999-09-14 Pola Chemical Industries Inc. Mineral absorption promoting agent
US5460957A (en) * 1992-04-28 1995-10-24 Maruha Corporation Calcium alginate oligosaccharide and method for producing the same from potassium or sodium alginate
JPH06237783A (ja) * 1993-02-17 1994-08-30 Maruha Corp アルギン酸カリウムオリゴ糖及びその製造法
JP3202365B2 (ja) * 1992-12-04 2001-08-27 株式会社紀文フードケミファ オリゴマンヌロン酸を重合度によって分離する方法
JPH1143439A (ja) * 1997-07-30 1999-02-16 Maruha Corp 血管内皮増殖促進剤
WO2000033791A2 (en) * 1998-12-11 2000-06-15 The Salk Institute For Biological Studies Co-factors for trophic factors, and methods of use thereof
JP4186294B2 (ja) * 1999-02-26 2008-11-26 セイコーエプソン株式会社 ポリグルロン酸の製造方法
KR100501584B1 (ko) 2000-02-03 2005-07-18 (주)케이비피 저분자 폴리만유로네이트의 제조방법, 혈청지질개선제로서의 이의 신규 용도 및 이를 함유하는 기능성식품 및 건강 보조 식품
JP3899843B2 (ja) 2000-05-12 2007-03-28 セイコーエプソン株式会社 ポリウロン酸の製造方法
CN1117766C (zh) 2000-09-07 2003-08-13 青岛海洋大学 单一聚合度的甘露糖醛酸的制备方法
CN1341664A (zh) 2000-09-07 2002-03-27 青岛海洋大学 聚甘露糖醛酸多糖的制备方法及应用
JP2002272420A (ja) * 2001-03-19 2002-09-24 Maruha Corp 抗高血圧関連摂取物
CN1161368C (zh) 2001-04-07 2004-08-11 青岛海洋大学 一种褐藻胶寡糖的制造方法
CN1160080C (zh) 2001-10-01 2004-08-04 青岛海洋大学 褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用
CN1401786A (zh) 2001-11-15 2003-03-12 青岛海洋大学 β－D－甘露糖醛酸寡糖单克隆抗体的制备方法
FR2840305B1 (fr) * 2002-05-29 2005-08-19 Ct D Etude Et De Valorisation Procedes d'obtention d'oligo-mannuronates et guluronates, les produits obtenus et leurs utilisations
CN1182146C (zh) * 2002-09-20 2004-12-29 青岛海洋大学 一种利用化学氧化制备褐藻胶寡糖的方法
CN1454992A (zh) 2003-05-16 2003-11-12 中国海洋大学 一种新的褐藻胶裂合酶及其制备方法和应用
CN1486988A (zh) 2003-08-04 2004-04-07 中国海洋大学 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物
CN1473836A (zh) 2003-08-04 2004-02-11 中国海洋大学 还原端1位为羧基的古罗糖醛酸寡糖及其衍生物
CN1562050A (zh) 2004-03-24 2005-01-12 中国海洋大学 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用

Also Published As

Publication number Publication date
EP1736160A4 (en) 2013-01-09
US10213456B2 (en) 2019-02-26
US9493496B2 (en) 2016-11-15
BRPI0509217B8 (pt) 2022-11-16
KR100844918B1 (ko) 2008-07-09
CA2561873A1 (en) 2005-09-29
PL1736160T3 (pl) 2016-01-29
NO341226B1 (no) 2017-09-18
UA85226C2 (ru) 2009-01-12
EA200601756A1 (ru) 2007-04-27
JP2007530718A (ja) 2007-11-01
US20150105344A1 (en) 2015-04-16
ZA200608813B (en) 2008-01-08
US20070254848A1 (en) 2007-11-01
US8835403B2 (en) 2014-09-16
BRPI0509217B1 (pt) 2020-09-24
ES2552218T3 (es) 2015-11-26
BRPI0509217A (pt) 2007-09-04
EP1736160B1 (en) 2015-08-26
DK1736160T3 (en) 2015-12-07
EA011417B1 (ru) 2009-02-27
NO20064825L (no) 2006-12-27
KR20070007397A (ko) 2007-01-15
CA2561873C (en) 2013-01-15
AU2005223923A1 (en) 2005-09-29
EP1736160A1 (en) 2006-12-27
AU2005223923B2 (en) 2008-10-23
HUE028071T2 (en) 2016-11-28
US20170112870A1 (en) 2017-04-27
CN1562050A (zh) 2005-01-12
US20190255092A1 (en) 2019-08-22
WO2005089776A1 (en) 2005-09-29
JP4709203B2 (ja) 2011-06-22
MA28971B1 (fr) 2007-11-01
PT1736160E (pt) 2015-11-20

Similar Documents

Publication Publication Date Title
BRPI0509217A8 (pt) oligossacarídeo alginato e seus derivados, sua preparação e seus usos
ES2293538T3 (es) Esteres de acido hialuronico con reina, procedimiento para su preparacion y composiciones que comprenden los mismos.
US20100256090A1 (en) Alginic Acid with Low Molecular Weight, Its Salts, Uses, Preparative Methods, Pharmaceutical Compositions and Foods
BRPI0514147A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratamento profilático ou terapêutico de uma condição onde a ativação de gk é desejável, de tratamento profilático ou terapêutico da hiperglicemia ou diabete e de prevenção da diabete em um ser humano que demosntra hiperglicemia pré-diabética ou toleráncia à glicose prejudicada, e, processo para a preparação do composto
JP2018510902A (ja) 創傷治癒調節のための製剤および方法
JPH06506917A (ja) 哺乳動物の細胞を保護および蘇生するための治療用組成物およびその製造および使用方法
TW200831106A (en) Antiinflammatory agent comprising 2-aminophenol or its derivatives as an effective ingredient(s)
CN113599391A (zh) 羧甲基壳聚糖用于促进皮肤伤口愈合、修复皮肤屏障的用途
DK0882033T3 (da) Benzofuran-acrylsyrederivater og deres anvendelse som modulatorer for RXRS- eller RARS-receptorer
CN103120642B (zh) 一种用于皮肤疾患的凝胶及其制备方法
BR0308576A (pt) Compostos: composições farmacêuticas para administração em um mamìfero e métodos para inibir a enzima citocroma p450rai em um mamìfero
CN100360141C (zh) 小牛血清去蛋白凝胶和小牛血清去蛋白眼用凝胶
NO20002008L (no) Løsning for peritonealdialyse og fremgangsmÕte for fremstilling derav
CN1102153C (zh) 水溶性壳聚糖的制备方法
CN114028265A (zh) 一种超分子包埋水杨酸及其制备方法
DE10015525A1 (de) Synthetische Derivate von Lunularsäure, Arzneimittel enthaltend diese Verbindung, Verfahren zur Herstellung der Lunularsäurederivate sowie deren Verwendung
ES2093226T3 (es) Retinoides sustituidos con un ciclo ditiano y su empleo, procedimiento de preparacion de dichos compuestos, composiciones cosmetica y farmaceutica que los contienen y empleo terapeutico de esta ultima.
CN115040501B (zh) 顺-13-十八碳烯酸或其盐化合物在制备促进受损皮肤和/或黏膜愈合的药物中的应用
CN103830266A (zh) 部分氧化海藻酸钠羧甲基化衍生物的制备方法和应用
KR927003536A (ko) 키누렌산 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물
CN105536037A (zh) 一种抗菌医用粘合剂及其制备方法
CN118161420A (zh) 一种抑制酪氨酸酶活性的胶原肽/壳寡糖复合物及其制备方法和应用
Yang et al. Mussel-inspired near-infrared light-responsive gelatin-based hydrogels for enhancing MRSA-infected wound healing
TW203011B (en) Pharmaceutical composition of powdered ascorbic acid
WO2024063715A1 (en) Effervescent tablet comprising l-arginine used for healing wounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2629 DE 25/05/2021, QUANTO AO ITEM (72) NOME DO INVENTOR.